Measuring biomarkers to assess the therapeutic effects of PPAR agonists?

Author： Chinetti-Gbaguidi Giulia   Staels Bart  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.8, Iss.11, 2007-11, pp. : 1567-1580

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

PPAR- agonists: therapeutic role in diabetes, inflammation and cancer

By Murphy G.J.   Holder J.C.  

Trends in Pharmacological Sciences, Vol. 21, Iss. 12, 2000-12 ,pp. : 469-474

Elsevier

Access to resources Recommend Favorite

Effects of PPAR&ggr; Agonists against Vascular and Renal Dysfunction

By  

Current Molecular Pharmacology, Vol. 5, Iss. 2, 2012-06 ,pp. : 248-254

Bentham Science Publishers

Access to resources Recommend Favorite

New Pharmacological Perspectives and Therapeutic Potential of PPAR-&ggr; Agonists

By  

Current Pharmaceutical Design, Vol. 10, Iss. 28, 2004-11 ,pp. : 3505-3524

Bentham Science Publishers

Access to resources Recommend Favorite

Neuroprotective effects of PPAR agonists against oxidative insults in HT-22 cells

By Aoun P.   Watson D.G.   Simpkins J.W.  

European Journal of Pharmacology, Vol. 472, Iss. 1, 2003-07 ,pp. : 65-71

Elsevier

Access to resources Recommend Favorite

Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer

By  

Current Medicinal Chemistry, Vol. 23, Iss. 7, 2016-02 ,pp. : 636-649

Bentham Science Publishers

Access to resources Recommend Favorite